| atrial fibrillation | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Karlson, 1998 | vs placebo | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 3.50 [0.77; 15.96] Pro-arrhythmia NaN [NaN; NaN] Atrial fibrillation recurrence 0.75 [0.54; 1.05] | | PRODIS, 1996 | vs placebo | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 0.40 [0.14; 1.19] Pro-arrhythmia 0.81 [0.05; 12.26] Atrial fibrillation recurrence 0.73 [0.37; 1.44] | | Lloyd (Disopyramide vs placebo), 1984 | vs placebo | | | all cause mortality NaN [NaN; NaN] Pro-arrhythmia NaN [NaN; NaN] Atrial fibrillation recurrence 0.81 [0.53; 1.24] | | Lloyd (Disopyramide vs quinidine), 1984 | vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Karlson, 1998 | Disopyramide 500 mg/d (n=46) vs. palcebo (n=46) | Persistent AF between 6 weeks and 1 year | open Parallel groups Sample size: 46/46 Primary endpoint: FU duration: 12 months | | PRODIS, 1996 | Disopyramide 750 mg/d (n=31) vs. propafenone 900 mg/d (n=25) | Persistent AF | double blind Parallel groups Sample size: 31/25 Primary endpoint: FU duration: 6 months | | Lloyd (Disopyramide vs placebo), 1984 | Disopyramide 450 mg/d , (n=29) vs. placebo
(n=25)
| Persistent AF lasting 1 month to 3 years
| double blind Parallel groups Sample size: 29/25 Primary endpoint: FU duration: 6 months
| | Lloyd (Disopyramide vs quinidine), 1984 | Disopyramide 450 mg/d ,
,
(n=29) vs. placebo
(n=28)
| Persistent AF lasting 1 month to 3 years
| double blind Parallel groups Sample size: 29/28 Primary endpoint: FU duration: 6 months
|
|
